Novartis Acquires Opexa’s Adult Stem Cell Technology
Biotech giant Novartis agrees to pay $4 million to Opexa Therapeutics for its proprietary adult stem cell technology.
August 7, 2009
Biotech giant Novartis agrees to pay $4 million to Opexa Therapeutics for its proprietary adult stem cell technology.
Scientists apply principles of proteomics to embryonic stem cells in order to learn more about cellular differentiation.
The pharmaceutical company Athersys Inc. has announced that it is seeking commercial partners for the development and testing of its stem cell and drug therapies.
The biotech company Genzyme has received approval from the European Commission for the use of its product Mozobil in the treatment of patients with lymphoma and multiple myeloma.
The biotech companies DARA BioSciences and America Stem Cell announce their collaboration in adult stem cell research for the treatment of hematological disorders.
Scientists in Japan have created a bioengineered tooth from mouse stem cells.